Details of the Drug Combination

General Information of Drug Combination (ID: DCIHJX7)

• Drug Combination Name: Erlotinib + Fusidic Acid
• Indication: Non-Small Cell Lung Cancer; Status: Phase 1 [1]
• Component Drugs:
  Erlotinib (DMCMBHA): Small molecular drug
  Fusidic Acid (DMWVCF3): Small molecular drug

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Erlotinib

Disease Entry	ICD 11	Status	REF
Adrenal gland neoplasm	N.A.	Approved	[2]
Adult hepatocellular carcinoma	N.A.	Approved	[2]
Brain cancer	2A00	Approved	[2]
Esophageal disorder	N.A.	Approved	[2]
Lung cancer	2C25.0	Approved	[2]
Non-small-cell lung cancer	2C25.Y	Approved	[3]
Pancreatic adenocarcinoma	N.A.	Approved	[2]
Psoriasis	EA90	Approved	[2]
Salivary gland squamous cell carcinoma	N.A.	Approved	[2]
Pancreatic cancer	2C10	Phase 3	[3]
Colon cancer	2B90.Z	Phase 2	[3]
Ependymoma	2A00.0Y	Investigative	[2]
Neoplastic meningitis	N.A.	Investigative	[2]
Neuroblastoma	2D11.2	Investigative	[2]

Erlotinib Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Epidermal growth factor receptor (EGFR)	TTGKNB4	EGFR_HUMAN	Inhibitor	[31]

Erlotinib Interacts with 2 DTP Molecule(s)

DTP Name	DTP ID	UniProt ID	Mode of Action	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[32]
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[33]

Erlotinib Interacts with 4 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Metabolism	[34]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Metabolism	[35]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Metabolism	[35]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Metabolism	[35]

Erlotinib Interacts with 1 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Epidermal growth factor receptor (EGFR)	OTAPLO1S	EGFR_HUMAN	Increases Response	[36]

Indication(s) of Fusidic Acid

Disease Entry	ICD 11	Status	REF
Acne vulgaris	ED80	Approved	[4]
Actinomycosis	N.A.	Approved	[5]
Acute gonococcal cervicitis	N.A.	Approved	[6]
Acute gonococcal epididymo-orchitis	N.A.	Approved	[6]
Anthrax	1B97	Approved	[7]
Bacteremia	1A73	Approved	[8]
Bacterial infection	1A00-1C4Z	Approved	[9]
Bartonellosis	N.A.	Approved	[6]
Blepharoconjunctivitis	N.A.	Approved	[10]
Boutonneuse fever	N.A.	Approved	[6]
Brill-Zinsser disease	N.A.	Approved	[6]
Bronchitis	CA20	Approved	[11]
Brucellosis	N.A.	Approved	[6]
Chancroid	N.A.	Approved	[6]
Chlamydiaceae infections	N.A.	Approved	[12]
Cholangitis	N.A.	Approved	[6]
Corneal abrasion	NA06.4	Approved	[13]
Cutaneous anthrax	N.A.	Approved	[6]
Dacryocystitis	N.A.	Approved	[14]
Demodex blepharitis	1G07	Approved	[6]
Endemic typhus	N.A.	Approved	[6]
Epidemic louse-borne typhus	N.A.	Approved	[6]
Folliculitis	N.A.	Approved	[15]
Gastrointestinal anthrax	N.A.	Approved	[6]
Inhalational anthrax	N.A.	Approved	[6]
Listeriosis	N.A.	Approved	[16]
Lymphogranuloma venereum	N.A.	Approved	[6]
Mycoplasma pneumoniae pneumonia	N.A.	Approved	[6]
Neonatal sepsis	N.A.	Approved	[17]
Ornithosis	N.A.	Approved	[6]
Paronychia	1F23.13	Approved	[18]
Peritonitis	N.A.	Approved	[19]
Pneumococcal infection	CA00-CA40	Approved	[20]
Pneumonia	CA40	Approved	[21]
Pseudomonas aeruginosa infectious disease	N.A.	Approved	[22]
Q fever	N.A.	Approved	[6]
Relapsing fever	N.A.	Approved	[6]
Rickettsialpox	N.A.	Approved	[6]
Rickettsiosis	N.A.	Approved	[6]
Rocky mountain spotted fever	N.A.	Approved	[6]
Rosacea	ED90.0	Approved	[23]
Staphylococcal pneumonia	N.A.	Approved	[24]
Staphylococcus aureus infection	N.A.	Approved	[25]
Streptococcus infection	1B53	Approved	[26]
Syphilis	N.A.	Approved	[27]
Trachoma	N.A.	Approved	[6]
Tularemia	1B94	Approved	[6]
Typhus	N.A.	Approved	[6]
Urinary tract infection	GC08	Approved	[28]
Yaws	N.A.	Approved	[6]
MRSA infection	1D01.0Y	Phase 3	[29]
Sinusitis	CA0A.Z	Investigative	[30]
Vibrio cholerae infection	1A00	Investigative	[6]

Fusidic Acid Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Streptococcus Elongation factor G (Stre-coc fusA)	TT6HP1T	EFG_STRZJ	Inhibitor	[8]

Fusidic Acid Interacts with 2 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DEYGVN4	UD11_HUMAN	Metabolism	[37]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Metabolism	[38]

Fusidic Acid Interacts with 3 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Bile salt export pump (ABCB11)	OTRU7THO	ABCBB_HUMAN	Decreases Activity	[39]
Solute carrier organic anion transporter family member 1B3 (SLCO1B3)	OTOM3BUH	SO1B3_HUMAN	Decreases Activity	[40]
Solute carrier organic anion transporter family member 1B1 (SLCO1B1)	OTNEN8QK	SO1B1_HUMAN	Decreases Activity	[40]

References

• [1] ClinicalTrials.gov (NCT00718315) A Study of Verutex (Fusidic Acid), Eritex (Erythromycin) and Fisiogel in the Management of Tarceva-Associated Rash.
• [2] Erlotinib FDA Label
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4920).
• [4] Curcumin/Fusidic Acid Bitherapy Loaded Mixed Micellar Nanogel for Acne Vulgaris Treatment: In Vitro and In Vivo Studies. AAPS PharmSciTech. 2023 Sep 11;24(7):182.
• [5] [In vitro sensitivity of Actinomyces israelii, Actinobacillus actinomycetem-comitans and Bacteroides melaninogenicus to cephalothin, cephaloridine, gentamicin, fusidic acid and lincomycin]. Int Z Klin Pharmakol Ther Toxikol. 1970 Oct;3(4):318-20.
• [6] A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
• [7] Cationic quaternized aminocalix[4]arenes: cytotoxicity, haemolytic and antibacterial activities. Int J Pharm. 2013 Dec 15;458(1):25-30.
• [8] Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus. Antimicrob Agents Chemother. 2009 May;53(5):2059-65.
• [9] Has nature already identified all useful antibacterial targets Curr Opin Microbiol. 2008 Oct;11(5):387-92.
• [10] Fusidic acid viscous eyedrops--an evaluation of pharmacodynamics, pharmacokinetics and clinical use for UK optometrists. Ophthalmic Physiol Opt. 2006 Jul;26(4):343-61.
• [11] [Interferon-gamma receptor 1 deficiency in a 19-month-old child: case report and literature review]. Zhonghua Er Ke Za Zhi. 2014 May;52(5):387-91.
• [12] The in vitro effects of proxymetacaine, fluorescein, and fusidic acid on real-time PCR assays used for the diagnosis of Feline herpesvirus 1 and Chlamydophila felis infections. Vet Ophthalmol. 2011 Sep;14 Suppl 1:5-8.
• [13] Antibiotic prophylaxis for corneal abrasion. Cochrane Database Syst Rev. 2022 May 27;5(5):CD014617.
• [14] [Susceptibility of drug-resistant staphylococci isolated from different parts of the ocular anterior segment to common ophthalmic antibiotics]. Zhonghua Yan Ke Za Zhi. 2022 Aug 11;58(8):598-605.
• [15] Fusidic acid betamethasone lipid cream. Int J Clin Pract. 2016 May;70 Suppl 184:4-13.
• [16] Antimicrobial Resistance of Listeria monocytogenes from Animal Foods to First- and Second-Line Drugs in the Treatment of Listeriosis from 2008 to 2021: A Systematic Review and Meta-Analysis. Can J Infect Dis Med Microbiol. 2022 Oct 7;2022:1351983.
• [17] Microbiological Characteristics and Resistance Patterns in a Neonatal Intensive Care Unit: A Retrospective Surveillance Study. Cureus. 2024 Mar 12;16(3):e56027.
• [18] Extensive pyomyositis secondary to paronychia-related MRSA infection: A case report. Medicine (Baltimore). 2022 Jan 14;101(2):e28431.
• [19] An experimental evaluation of the pharmacokinetics of fusidic acid in peritoneal dialysis. J Med Microbiol. 1992 Feb;36(2):71-7.
• [20] Epidemiology of penicillin resistant pneumococci in Iceland. Microb Drug Resist. 1995 Summer;1(2):121-5.
• [21] Mycoplasma pneumoniae-associated mucositis. BMJ Case Rep. 2021 Apr 15;14(4):e239086.
• [22] Bacterial profile of diabetic foot infections and antibiotic susceptibility in a specialized diabetes centre in Cameroon. Pan Afr Med J. 2022 May 18;42:52.
• [23] Placebo controlled trial of fusidic acid gel and oxytetracycline for recurrent blepharitis and rosacea. Br J Ophthalmol. 1995 Jan;79(1):42-5.
• [24] Fusidic acid in other infections. Int J Antimicrob Agents. 1999 Aug;12 Suppl 2:S11-5.
• [25] Registered and investigational drugs for the treatment of methicillin-resistant Staphylococcus aureus infection. Recent Pat Antiinfect Drug Discov. 2008 Jan;3(1):10-33.
• [26] Impetigo: diagnosis and treatment. Am Fam Physician. 2014 Aug 15;90(4):229-35.
• [27] Balanoposthitis and Penile Edema: Atypical Manifestations of Primary Syphilis. Sex Transm Dis. 2015 Sep;42(9):524-5.
• [28] Isolation of Staphylococcus aureus Urinary Tract Infections at a Community-Based Healthcare Center in Riyadh. Cureus. 2023 Feb 18;15(2):e35140.
• [29] Application of pharmacokinetic-pharmacodynamic modeling and the justification of a novel fusidic acid dosing regimen: raising Lazarus from the dead. Clin Infect Dis. 2011 Jun;52 Suppl 7:S513-9.
• [30] Facial cellulitis associated with Pseudomonas aeruginosa complicating ophthalmic herpes zoster. Dermatol Online J. 2004 Oct 15;10(2):20.
• [31] Quantitative prediction of fold resistance for inhibitors of EGFR. Biochemistry. 2009 Sep 8;48(35):8435-48.
• [32] Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice. Mol Cancer Ther. 2008 Aug;7(8):2280-7.
• [33] Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy. Adv Drug Deliv Rev. 2009 Jan 31;61(1):26-33.
• [34] In vitro assessment of time-dependent inhibitory effects on CYP2C8 and CYP3A activity by fourteen protein kinase inhibitors. Drug Metab Dispos. 2014 Jul;42(7):1202-9.
• [35] Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706.
• [36] Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004 May 20;350(21):2129-39. doi: 10.1056/NEJMoa040938. Epub 2004 Apr 29.
• [37] Fusidic acid inhibits hepatic transporters and metabolic enzymes: potential cause of clinical drug-drug interaction observed with statin coadministration. Antimicrob Agents Chemother. 2016 Sep 23;60(10):5986-94.
• [38] The potent mechanism-based inactivation of CYP2D6 and CYP3A4 with fusidic acid in in vivo bioaccumulation. Xenobiotica. 2018 Oct;48(10):999-1005.
• [39] Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
• [40] Inhibition of Hepatobiliary Transport Activity by the Antibacterial Agent Fusidic Acid: Insights into Factors Contributing to Conjugated Hyperbilirubinemia/Cholestasis. Chem Res Toxicol. 2016 Oct 17;29(10):1778-1788. doi: 10.1021/acs.chemrestox.6b00262. Epub 2016 Oct 4.